Sep 19, 2026, 23:31 UTC
SBS Law announced a fraud investigation into Cellectis S.A. and invited CLLS investors to join it.
Source:Sep 17, 2026, 18:45 UTC
Holzer & Holzer, LLC announced an investigation into whether Cellectis S.A. complied with federal securities laws after Cellectis said it would exit development of lasme-cel and eti-cel.
Source:Sep 14, 2026, 06:40 UTC
Cellectis announced that its board of directors approved a strategic transformation to become an in vivo gene editing company focused on developing long-lasting treatments for chronic diseases.
Source:Jun 25, 2026, 20:30 UTC
Cellectis held its shareholders general meeting on June 25, 2026, where resolutions 1 through 29 were adopted and resolution 30 was rejected.
Source:Jun 9, 2026, 20:30 UTC
The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy designation to Cellectis' lasme-cel for relapsed or refractory B-cell acute lymphoblastic leukemia.
Source: